uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts

Wall Street is turning constructive connected 3 clinical-stage biotechs simultaneously, each sitting astatine the borderline of a binary catalyst. The expert calls connected uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) stock a communal thread: analysts spot asymmetric upside successful names wherever the marketplace has not yet priced successful the afloat probability of success.

The astir melodramatic telephone belongs to uniQure. RBC Capital expert Luca Issi upgraded the banal to Outperform from Sector Perform with a terms people of $35, up from $11. Wells Fargo besides upgraded uniQure to Overweight from Equal Weight with a $60 terms target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this arsenic a affirmative for uniQure, noting it is "not inconceivable" that the FDA reverts to its anterior stance, and believes Prasad's departure is apt to unfastened up a much balanced treatment connected risk/reward for Huntington's disease. RBC present places a 50% accidental the cause yet gets approved.

The objective information underpinning that presumption is meaningful. AMT-130's Phase I/II 36-month information showed statistically important 75% slowing successful illness progression connected cUHDRS (p=0.003) and 60% slowing connected TFC (p=0.033). The FDA's January 2026 directive requires a afloat randomized, double-blind, sham surgery-controlled Phase III proceedings earlier immoderate selling application, and uniQure has a Type B gathering with the FDA planned for Q2 2026 to sermon Phase III survey design.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

The banal presently trades astatine $16.52, good beneath some terms targets. The statement expert people sits astatine $28.45, with 10 bargain ratings and 3 holds crossed the sum universe. The banal has surged 53.33% implicit the past week arsenic the upgrade rhythm took hold, though it remains down 32.72% year-to-date from its January levels. The binary quality of an FDA result remains a cardinal consideration. uniQure does clasp $622.5M successful currency with runway into H2 2029, limiting near-term dilution risk.